RxDoctor Payments Data

Christina Payne, MD

Rheumatology · la Jolla, CANPI 1679912661

Payments from drug & device makers

$31,275in general payments, 2019–2025

Across 242 payments — averaging $129.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$26K
  • Novartis$1K
  • AstraZeneca$946
  • AbbVie$744
  • Johnson & Johnson$507
  • Pfizer$410
  • plus $1K from 11 others

What the payments were for

  • Consulting fees$3,04010%
  • Speaking & faculty fees$18,70060%
  • Travel & lodging$9793%
  • Food & beverage$8,44627%
  • Education$1100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,275 in reported general payments places this provider in the 80th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California

Medicare billing

Part B allowed, 2024
$41,954
Medicare patients
135
Services billed
630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab32$388,783
Enbrel MiniEtanercept13$94,371
Humira(Cf)Adalimumab12$81,740
Enbrel SureclickEtanercept12$79,663
Actemra ActpenTocilizumab17$55,681
Hydroxychloroquine Sulfate240$10,366
Mycophenolate Mofetil39$6,317
MethotrexateMethotrexate Sodium186$4,270
Cevimeline Hcl24$3,725
Leflunomide37$2,721
Colchicine18$2,626
Pilocarpine Hcl13$1,869
Azathioprine14$1,395
Nifedipine ErNifedipine25$621
Prednisone79$551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf)$744$81,74012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 808 rheumatology providers in California.

Other rheumatology in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →